[Skip to Content]

Upstate Active Clinical Trials

Study Title:

A Phase-1, Placebo-controlled, Randomized, Observer-blind, Dose-finding Study to Evaluate the Safety, Tolerability, and Immunogenicity of Self-amplifying RNA Vaccine Preparations against Influenza in Healthy Individuals

What is the purpose of the study? (in Layman's terms, please describe the study)

Objective is to find the most effective dose and formulation to be effective against flu. A self-amplifying RNA vaccine should have greater effectiveness than the conventional vaccines now licensed. Moreover, since RNA vaccines can be produced much more quickly, a better match with prevailing strains of flu is possible.

Upstate Institutional Review Board (IRB) Number:


Study/Protocol ID:

Pfizer C4861001

Study Phase:


Patient Age Group:


Principal Investigator:

Stephen J Thomas

Who is eligible?

Healthy adults 18-55 years old

What is involved if I participate?

  • How long is the study?
    Expected to end phase 1 in August 2023
  • Is transportation provided or reimbursed?
  • Is parking provided or reimbursed?
  • What tests and procedures are involved?
    ECG, blood draws, immunization

Where will the study take place?

Global Health Research Unit, Community Campus, 4900 Broad Rd. POB-North Suite 4U, Syracuse NY 13215

Other Information:

For more information, please call 315-464-9869.

Who can I contact for more information?

Name: William Gregory
Phone: 315-464-5225
Email: gregoryw@upstate.edu

Return to Previous Page || Search Again